New On-Demand Investor Conference Showcases Nine Emerging Biotech and Healthcare Firms

The Virtual Investor “Why Now” On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, concluded on August 27, 2026, providing investors and analysts direct access to management teams presenting why now is the right time for their companies. The on‑demand format emphasizes transparency and flexibility, enabling participants to review presentations at their convenience.

The program featured nine innovative healthcare and biotech companies, including AIM ImmunoTech, Akari Therapeutics, CNS Pharmaceuticals, Dare Bioscience, enVVeno Medical, Ernexa Therapeutics, GRI Bio, Moleculin Biotech, and Outlook Therapeutics.

AIM ImmunoTech (AIM), an immune‑oncology firm advancing Ampligen in the Phase 2 DURIPANC trial for metastatic pancreatic cancer, highlighted final patient dosing and primary‑endpoint analysis scheduled for Q4 2026, with top‑line results expected in Q1 2027. Ampligen (rintatolimod) is a highly selective TLR3 agonist that has demonstrated broad‑spectrum activity, including combination work with AstraZeneca’s Imfinzi. AIM closed at $0.25, up 3.36%.

Akari Therapeutics (AKTX), an oncology biotech developing antibody‑drug conjugates powered by a proprietary PH1 RNA‑splicing payload, outlined its differentiated ADC platform. CEO Abizer Gaslightwala highlighted lead candidates AKTX‑101 (Trop2‑targeting, IND‑enabling, Phase 1 planned for mid‑2027) and AKTX‑102 (CEACAM5‑targeting). AKTX closed at $10.70, up 18.76%.

CNS Pharmaceuticals (CNSP), a biotechnology company focused on novel anticancer therapies that can cross the blood‑brain barrier, emphasized a strengthened leadership team and disciplined asset strategy. President & CEO Rami Levin discussed the advancement of Berubicin for glioblastoma and TPI‑a87, a taxane derivative. CNSP closed at $5.52, up 0.10%.

Moleculin Biotech (MBRX), a Phase 3 clinical‑stage oncology firm, highlighted encouraging interim results from the pivotal MIRACLE trial of Annamycin in relapsed/refractory AML. Chairman & CEO Walter noted a forthcoming 90‑patient interim analysis, positioning the drug as a potential registration catalyst. The pipeline also includes programs in soft‑tissue sarcoma, WP1066, and WP1122. MBRX closed at $0.64, down 5.63%.

Ernexa Therapeutics (ERNA), an innovator developing engineered iMSC therapies that deliver IL‑7/IL‑15 directly into the tumor microenvironment, reported progress on lead candidate ERNA‑101. CEO Sanjeev Luther indicated IND submission is targeted for Q3 2026, with a Phase 1 trial in platinum‑resistant ovarian cancer slated for Q4 2026. ERNA closed at $4.57, down 2.14%.

GRI Bio (GRI), a clinical‑stage biotechnology company targeting inflammatory, fibrotic and autoimmune diseases, presented late‑breaking Phase 2a data for its once‑daily oral RARß/α agonist GRI‑0621 in idiopathic pulmonary fibrosis. CEO Marc Hertz, PhD, highlighted improvements in lung function and anti‑fibrotic biomarkers, along with favorable tolerability. The pipeline also includes GRI‑0803 for systemic lupus. GRI closed at $1.92, down 7.25%.

Daré Bioscience (DARE), a purpose‑driven health biotechnology firm focused on women’s health, showcased its mission‑driven portfolio. CEO Sabrina Martucci Johnson highlighted the first product Flora Sync LF5, the Phase 3 hormone‑free contraceptive Ovaprene, and DARE to PLAY Sildenafil Cream. The DARE‑HPV therapeutic entered Phase 2 with an ARPA‑H award, expecting top‑line data in 2027. DARE closed at $0.73, down 0.50%.

enVVeno Medical (NVNO), a late‑clinical‑stage medical‑device company advancing bioprosthetic solutions for deep venous disease, presented its investment thesis. CEO Robert Berman underscored the recent FDA IDE approval for the pivotal TAVVE trial, scheduled to start in Q4 2026 across roughly 230 patients. The trial marks a critical regulatory milestone toward potential approval of the enVVe System. NVNO closed at $10.75, down 6.28%.

Outlook Therapeutics (OTLK), a biopharmaceutical company focused on retinal disease, highlighted its transformative period following FDA approval of LYTENAVA (bevacizumab‑vikg) on July 24, 2026, the only FDA‑approved ophthalmic formulation of bevacizumab for wet AMD in the U.S. CEO Bob Jahr emphasized the shift from development to commercial operations, U.S. launch preparations, and guidance that annual U.S. LYTENAVA sales could exceed $500 million by 2030. OTLK closed at $0.64, up 0.59%.

Source link